Immatics (IMTX) Reports Q3 Loss, Lags Revenue Estimates
Immatics: Q3 Earnings Snapshot
Immatics Announces Third Quarter 2026 Financial Results and Business Update
Immatics Q3 EPS $(0.58) Misses $(0.49) Estimate, Sales $7.968M Miss $10.230M Estimate
Immatics (IMTX) PRAME Data Puts A Pricey Valuation Back In Focus
Immatics (IMTX) Stock Looks Stretched As PRAME Trial Data Impresses
Reported Saturday, Immatics Reports IMA203CD8 Cell Therapy 51% ORR, 41% cORR Across Multiple Solid Tumors With Manageable Safety; IMA402 Bispecific Shows 32% cORR In PRAME-High Melanoma, Favorable Safety Profile
Should Updated Trial Results Require Action From Immatics (IMTX) Investors?
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Stifel Initiates Coverage On Immatics with Buy Rating, Announces Price Target of $15
Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma
Immatics Announces $150 Million Underwritten Offering
Immatics Announces $150M Underwritten Offering Of Ordinary Shares And Pre-Funded Warrants
Immatics Announces Second Quarter 2026 Financial Results and Business Update
Immatics Q2 EPS $(0.53) Misses $(0.43) Estimate, Sales $10.630M Miss $14.590M Estimate
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
Immatics: PRAME Is Becoming More Than A Single-Asset Story
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Immatics Announces Extended Data From Phaseb Clinicla Trial Evaluating Anzu-Cel PRAME TCR T-Cell Therapy In Heavily Pretreated Patients With Advanced Melanoma At ASCO Annual Meeting
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.